151 related articles for article (PubMed ID: 15587928)
1. Suramin as a chemosensitizer: oral pharmacokinetics in rats.
Ogden A; Wientjes MG; Au JL
Pharm Res; 2004 Nov; 21(11):2058-63. PubMed ID: 15587928
[TBL] [Abstract][Full Text] [Related]
2. Evidence of an absorption phase after short intravenous suramin infusions.
Hutson PR; Tutsch K; Spriggs D; Christian M; Rago R; Mutch R; Wilding G
Cancer Chemother Pharmacol; 1993; 31(6):495-9. PubMed ID: 8453691
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
[TBL] [Abstract][Full Text] [Related]
4. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
5. Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Chen D; Song SH; Wientjes MG; Yeh TK; Zhao L; Villalona-Calero M; Otterson GA; Jensen R; Grever M; Murgo AJ; Au JL
Pharm Res; 2006 Jun; 23(6):1265-74. PubMed ID: 16715360
[TBL] [Abstract][Full Text] [Related]
6. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.
Zhong DF; Li K; Xu JH; Du Y; Zhang YF
Acta Pharmacol Sin; 2003 Mar; 24(3):256-62. PubMed ID: 12617776
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
[TBL] [Abstract][Full Text] [Related]
9. Distribution of [14C]suramin in tissues of male rats following a single intravenous dose.
McNally WP; DeHart PD; Lathia C; Whitfield LR
Life Sci; 2000 Sep; 67(15):1847-57. PubMed ID: 11043607
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.
Egorin MJ; Yuan ZM; Sentz DL; Plaisance K; Eiseman JL
Cancer Chemother Pharmacol; 1999; 43(6):445-53. PubMed ID: 10321503
[TBL] [Abstract][Full Text] [Related]
11. Absorption and enterohepatic circulation of baicalin in rats.
Xing J; Chen X; Zhong D
Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266
[TBL] [Abstract][Full Text] [Related]
12. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
[TBL] [Abstract][Full Text] [Related]
14. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Charmandari E; Johnston A; Brook CG; Hindmarsh PC
J Endocrinol; 2001 Apr; 169(1):65-70. PubMed ID: 11250647
[TBL] [Abstract][Full Text] [Related]
16. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration.
Boinpally RR; Zhou SL; LoRusso PM; Parchment RE
Cancer Chemother Pharmacol; 2005 Apr; 55(4):404-407. PubMed ID: 15592839
[TBL] [Abstract][Full Text] [Related]
19. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
